|
1
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006.
|
|
2
|
Dicken BJ, Bigam DL, Cass C, Mackey JR,
Joy AA and Hamilton SM: Gastric adenocarcinoma - Review and
considerations for future directions. Ann Surg. 241:27–39.
2005.PubMed/NCBI
|
|
3
|
Vauhkonen M, Vauhkonen H and Sipponen P:
Pathology and molecular biology of gastric cancer. Best Pract Res
Clin Gastroenterol. 20:651–674. 2006. View Article : Google Scholar
|
|
4
|
Milne AN, Carneiro F, O’Morain C and
Offerhaus GJ: Nature meets nurture: molecular genetics of gastric
cancer. Hum Genet. 126:615–628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bernier I and Jolles P: Purification and
characterization of a basic 23 kDa cytosolic protein from bovine
brain. Biochim Biophys Acta. 790:174–181. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hori N, Chae KS, Murakawa K, Matoba R,
Fukushima A, Okubo K, et al: A human cDNA sequence homologue of
bovine phosphatidylethanolamine-binding protein. Gene. 140:293–294.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seddiqi N, Bollengier F, Alliel PM, Périn
JP, Bonnet F, Bucquoy S, et al: Amino acid sequence of the Homo
sapiens brain 21–23-kDa protein (neuropolypeptide h3), comparison
with its counterparts from Rattus norvegicus and Bos taurus
species, and expression of its mRNA in different tissues. J Mol
Evol. 39:655–660. 1994.
|
|
8
|
Yeung K, Seitz T, Li S, Janosch P,
McFerran B, Kaiser C, et al: Suppression of Raf-1 kinase activity
and MAP kinase signalling by RKIP. Nature. 401:173–177. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yeung K, Janosch P, McFerran B, Rose DW,
Mischak H, Sedivy JM, et al: Mechanism of suppression of the
Raf/MEK/extracellular signal-regulated kinase pathway by the raf
kinase inhibitor protein. Mol Cell Biol. 20:3079–3085. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeung KC, Rose DW, Dhillon AS, Yaros D,
Gustafsson M, Chatterjee D, et al: Raf kinase inhibitor protein
interacts with NF-kappaB-inducing kinase and TAK1 and inhibits
NF-kappaB activation. Mol Cell Biol. 21:7207–7217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lorenz K, Lohse MJ and Quitterer U:
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to
GRK-2. Nature. 426:574–579. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Mulla F, Hagan S, Al-Ali W, Jacob SP,
Behbehani AI, Bitar MS, et al: Raf kinase inhibitor protein:
mechanism of loss of expression and association with genomic
instability. J Clin Pathol. 61:524–529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klysik J, Theroux SJ, Sedivy JM, Moffit JS
and Boekelheide K: Signaling crossroads: The function of Raf kinase
inhibitory protein in cancer, the central nervous system and
reproduction. Cell Signal. 20:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Granovsky AE and Rosner MR: Raf kinase
inhibitory protein: a signal transduction modulator and metastasis
suppressor. Cell Res. 18:452–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akaishi J, Onda M, Asaka S, Okamoto J,
Miyamoto S, Nagahama M, et al: Growth-suppressive function of
phosphatidylethanolamine-binding protein in anaplastic thyroid
cancer. Anticancer Res. 26:4437–4442. 2006.PubMed/NCBI
|
|
16
|
Houben R, Michel B, Vetter-Kauczok CS,
Pföhler C, Laetsch B, Wolter MD, et al: Absence of classical MAP
kinase pathway signalling in Merkel cell carcinoma. J Invest
Dermatol. 126:1135–1142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Ouyang GL, Yi H, Li MY, Zhang PF,
Li C, et al: Identification of RKIP as an Invasion Suppressor
Protein in nasopharyngeal carcinoma by proteomic analysis. J
Proteome Res. 7:5254–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu Z, Smith PC, Zhang L, Rubin MA, Dunn
RL, Yao Z, et al: Effects of raf kinase inhibitor protein
expression on suppression of prostate cancer metastasis. J Natl
Cancer Inst. 95:878–889. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chatterjee D, Bai Y, Wang Z, Beach S, Mott
S, Roy R, et al: RKIP sensitizes prostate and breast cancer cells
to drug-induced apoptosis. J Biol Chem. 279:17515–17523. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schuierer MM, Bataille F, Hagan S, Kolch W
and Bosserhoff AK: Reduction in Raf kinase inhibitor protein
expression is associated with increased Ras-extracellular
signal-regulated kinase signaling in melanoma cell lines. Cancer
Res. 64:5186–5192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schuierer MM, Bataille F, Weiss TS,
Hellerbrand C and Bosserhoff AK: Raf kinase inhibitor protein is
downregulated in hepatocellular carcinoma. Oncol Rep. 16:451–456.
2006.PubMed/NCBI
|
|
22
|
Zhang L, Fu Z, Binkley C, Giordano T,
Burant CF, Logsdon CD, et al: Raf kinase inhibitory protein
inhibits beta-cell proliferation. Surgery. 136:708–715. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hagan S, Al-Mulla F, Mallon E, Oien K,
Ferrier R, Gusterson B, et al: Reduction of Raf-1 kinase inhibitor
protein expression correlates with breast cancer metastasis. Clin
Cancer Res. 11:7392–7397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee HC, Tian B, Sedivy JM, Wands JR and
Kim M: Loss of Raf kinase inhibitor protein promotes cell
proliferation and migration of human hepatoma cells.
Gastroenterology. 131:1208–1217. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Al-Mulla F, Hagan S, Behbehani AI, Bitar
MS, George SS, Going JJ, et al: Raf kinase inhibitor protein
expression in a survival analysis of colorectal cancer patients. J
Clin Oncol. 24:5672–5679. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li HZ, Wang Y, Gao Y, Shao J, Zhao XL,
Deng WM, et al: Effects of raf kinase inhibitor protein expression
on metastasis and progression of human epithelial ovarian cancer.
Mol Cancer Res. 6:917–928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinho O, Gouveia A, Silva P, Pimenta A,
Reis RM and Lopes JM: Loss of RKIP expression is associated with
poor survival in GISTs. Virchows Arch. 455:277–284. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R,
Rhodes D, et al: Metastasis suppressor gene Raf kinase inhibitor
protein (RKIP) is a novel prognostic marker in prostate cancer.
Prostate. 66:248–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zlobec I, Baker K, Minoo P, Jass JR,
Terracciano L and Lugli A: Node-negative colorectal cancer at high
risk of distant metastasis identified by combined analysis of lymph
node status, vascular invasion, and Raf-1 kinase inhibitor protein
expression. Clin Cancer Res. 14:143–148. 2008. View Article : Google Scholar
|
|
30
|
Martinho O, Granja S, Jaraquemada T,
Caeiro C, Miranda-Gonçalves V, Honavar M, et al: Downregulation of
RKIP is associated with poor outcome and malignant progression in
gliomas. PLoS One. 7:e307692012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chatterjee D, Sabo E, Tavares R and
Resnick MB: Inverse association between Raf Kinase Inhibitory
Protein and signal transducers and activators of transcription 3
expression in gastric adenocarcinoma patients: implications for
clinical outcome. Clin Cancer Res. 14:2994–3001. 2008. View Article : Google Scholar
|
|
32
|
Wang J, Yang YH, Wang AQ, Yao B, Xie G,
Feng G, et al: Immunohistochemical detection of the Raf kinase
inhibitor protein in nonneoplastic gastric tissue and gastric
cancer tissue. Med Oncol. 27:219–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jia B, Liu H, Kong Q and Li B: RKIP
expression associated with gastric cancer cell invasion and
metastasis. Tumour Biol. 33:919–925. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pinheiro C, Longatto-Filho A, Simões K,
Jacob CE, Bresciani CJ, Zilberstein B, et al: The prognostic value
of CD147/EMMPRIN is associated with monocarboxylate transporter 1
co-expression in gastric cancer. Eur J Cancer. 45:2418–2424. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fenoglio-Preiser C, Carneiro F, Powell SM,
et al: Tumors of the stomach. Pathology and Genetics of Tumors of
the Digestive System. Hamilton LAA: Lyon: IARC Press; pp. 37–66.
2000
|
|
36
|
Lauren T: The two histologic main types of
gastric carcinoma. Acta Pathol Microbiol Scand. 64:341962.
|
|
37
|
Ming SC: Gastric carcinoma. A
pathobiological classification. Cancer. 39:2475–85. 1977.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Greene FL, Page DL, Fleming ID, et al:
AJCC Cancer Staging Manual. 6th edition. Springer; New York: 2002,
View Article : Google Scholar
|
|
39
|
Martinho O, Faloppa CC, Scapulatempo Neto
C, Longatto-Filho A, Baiocchi G, Werneck da Cunha I, et al: Loss of
RKIP expression during the carcinogenic evolution of endometrial
cancer. J Clin Pathol. 65:122–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Desai AM, Pareek M, Nightingale PG and
Fielding JW: Improving outcomes in gastric cancer over 20 years.
Gastric Cancer. 7:196–203. 2004.PubMed/NCBI
|
|
41
|
Gabbert HE, Muller W, Schneiders A, Meier
S and Hommel G: The relationship of p53 expression to the prognosis
of 418 patients with gastric carcinoma. Cancer. 76:720–726. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Utsunomiya T, Yonezawa S, Sakamoto H,
Kitamura H, Hokita S, Aiko T, et al: Expression of MUC1 and MUC2
mucins in gastric carcinomas: its relationship with the prognosis
of the patients. Clin Cancer Res. 4:2605–2614. 1998.PubMed/NCBI
|
|
43
|
Yonemura Y, Nojima N, Kaji M, Fujimura T,
Itoh H, Ninomiya I, et al: E-cadherin and urokinase-type
plasminogen activator tissue status in gastric carcinoma. Cancer.
76:941–953. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Washington K, Gottfried MR and Telen MJ:
Expression of the cell adhesion molecule CD44 in gastric
adenocarcinomas. Hum Pathol. 25:1043–1049. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Minoo P, Zlobec I, Baker K, Tornillo L,
Terracciano L, Jass JR, et al: Loss of Raf-1 kinase inhibitor
protein expression is associated with tumor progression and
metastasis in colorectal cancer. Am J Clin Pathol. 127:820–827.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zaravinos A, Kanellou P, Baritaki S,
Bonavida B and Spandidos DA: BRAF and RKIP are significantly
decreased in cutaneous squamous cell carcinoma. Cell Cycle.
8:1402–1408. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Minoo P, Baker K, Goswami R, Chong G,
Foulkes WD, Ruszkiewicz AR, et al: Extensive DNA methylation in
normal colorectal mucosa in hyperplastic polyposis. Gut.
55:1467–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jazirehi AR, Vega MI, Chatterjee D,
Goodglick L and Bonavida B: Inhibition of the Raf-MEK1/2-ERK1/2
signaling pathway, Bcl-xL down-regulation, and chemosensitization
of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res.
64:7117–7126. 2004.PubMed/NCBI
|
|
49
|
Bonavida B, Baritaki S, Huerta-Yepez S,
Vega MI, Chatterjee D and Yeung K: Novel therapeutic applications
of nitric oxide donors in cancer: roles in chemo- and
immunosensitization to apoptosis and inhibition of metastases.
Nitric Oxide. 19:152–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Baritaki S, Yeung K, Palladino M, Berenson
J and Bonavida B: Pivotal roles of snail inhibition and RKIP
induction by the proteasome inhibitor NPI-0052 in tumor cell
chemoimmunosensitization. Cancer Res. 69:8376–8385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Baritaki S, Chapman A, Yeung K, Spandidos
DA, Palladino M and Bonavida B: Inhibition of epithelial to
mesenchymal transition in metastatic prostate cancer cells by the
novel proteasome inhibitor, NPI-0052: pivotal roles of Snail
repression and RKIP induction. Oncogene. 28:3573–3585. 2009.
View Article : Google Scholar
|
